Pricing Log in Create free account

Cartesian Therapeutics, Inc. (RNAC) vs Sol-Gel Technologies Ltd. (SLGL)

Cartesian Therapeutics, Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. Cartesian Therapeutics, Inc. is the larger, with a market value of $229.7M against $199.8M — 1.1× the size. Sol-Gel Technologies Ltd. grew revenue faster over the last twelve months: −92.5% against −94.8%. Cartesian Therapeutics, Inc. has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (0.00% vs −6,630.2%). Across the 16 metrics below, Cartesian Therapeutics, Inc. leads on 8 and Sol-Gel Technologies Ltd. on 8.

Valuation

Metric RNAC SLGL Biotechnology median
P/E n/m n/m 10.60
P/S 125.01 111.18 9.40
P/B n/m 4.15 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 77.39 120.87 9.02
Earnings yield (78.75%) (9.24%) (32.88%)
Free cash flow yield (35.43%) (10.66%) (23.13%)

Profitability

Metric RNAC SLGL Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity 236.88% (40.85%) (51.96%)
Return on assets (42.77%) (35.11%) (46.06%)
Return on invested capital 0.00% (6,630.24%) 0.00%

Growth

Metric RNAC SLGL Biotechnology median
Revenue growth (TTM) (94.81%) (92.50%) 6.76%
EPS growth (last fiscal year) (11.80%) 42.37% 29.88%
Revenue growth, 5-year CAGR (29.96%) 17.19% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RNAC SLGL Biotechnology median
Debt to equity (0.42) 0.00 0.00
Current ratio 7.48 10.37 4.97
Net debt to EBITDA 0.89 3.23 1.01

Dividend

Metric RNAC SLGL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric RNAC SLGL Biotechnology median
Market cap 229.69m 199.75m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack